title: Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.
abstract: Elevated extracellular glutamate, resulting from a loss of astrocytic glutamate transport capacity, may contribute to excitotoxic motor neuron (MN) damage in ALS. Accounting for their high excitotoxic vulnerability, MNs possess large numbers of unusual Ca(2+)-permeable AMPA channels (Ca-AMPA channels), the activation of which triggers mitochondrial Ca(2+) overload and strong reactive oxygen species (ROS) generation. However, the causes of the astrocytic glutamate transport loss remain unexplained. To assess the role of Ca-AMPA channels on the evolution of pathology in vivo, we have examined effects of prolonged intrathecal infusion of the Ca-AMPA channel blocker, 1-naphthyl acetylspermine (NAS), in G93A transgenic rat models of ALS. In wild-type animals, immunoreactivity for the astrocytic glutamate transporter, GLT-1, was particularly strong around ventral horn MNs. However, a marked loss of ventral horn GLT-1 was observed, along with substantial MN damage, prior to onset of symptoms (90-100 days) in the G93A rats. Conversely, labeling with the oxidative marker, nitrotyrosine, was increased in the neuropil surrounding MNs in the transgenic animals. Compared to sham-treated G93A animals, 30-day NAS infusions (starting at 67+/-2 days of age) markedly diminished the loss of both MNs and of astrocytic GLT-1 labeling. These observations are compatible with the hypothesis that activation of Ca-AMPA channels on MNs contributes, likely in part through oxidative mechanisms, to loss of glutamate transporter in surrounding astrocytes.
authors: Department of Neurology, University of California, Irvine, CA 92697, USA.
authors: Hong Z
authors: HZ
authors: Yin
authors: Darryl T
authors: DT
authors: Tang
authors: John H
authors: JH
authors: Weiss
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000473:pathology*; D000818:Animals; D030801:Animals, Genetically Modified; D001253:Astrocytes / Q000187:drug effects*; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage*; D027342:Excitatory Amino Acid Transporter 2 / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D008297:Male; D009046:Motor Neurons / Q000187:drug effects*; D051381:Rats; D013096:Spermine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013482:Superoxide Dismutase / Q000235:genetics
chemical_list: D018691:Excitatory Amino Acid Antagonists; D027342:Excitatory Amino Acid Transporter 2; D005904:Glial Fibrillary Acidic Protein; C067506:1-naphthylacetylspermine; D013096:Spermine; C109415:SOD1 G93A protein; D013482:Superoxide Dismutase
references: J Neurosci Methods. 2003 Jun 30;126(2):165-73
references: 12814841
references: J Neurosci. 2003 Apr 1;23(7):2627-33
references: 12684448
references: Science. 2003 Oct 3;302(5642):113-7
references: 14526083
references: Trends Neurosci. 2004 Jan;27(1):17-23
references: 14698606
references: J Neurosci. 2004 Aug 25;24(34):7566-75
references: 15329404
references: Hum Mol Genet. 2004 Oct 1;13(19):2183-96
references: 15294873
references: J Neuropathol Exp Neurol. 2004 Sep;63(9):964-77
references: 15453095
references: Neurosci Lett. 1989 Oct 9;104(3):258-62
references: 2812542
references: N Engl J Med. 1992 May 28;326(22):1464-8
references: 1349424
references: Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6591-5
references: 8393571
references: Ann Neurol. 1995 Jul;38(1):73-84
references: 7611729
references: Neuroreport. 1995 Apr 19;6(6):945-8
references: 7612889
references: J Neurochem. 1995 Aug;65(2):643-51
references: 7616220
references: Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3155-60
references: 8610185
references: J Neurosci. 1996 Jul 1;16(13):4069-79
references: 8753869
references: Ann Neurol. 1997 Sep;42(3):326-34
references: 9307254
references: Ann Neurol. 1997 Oct;42(4):644-54
references: 9382477
references: J Physiol. 1998 Aug 15;511 ( Pt 1):105-17
references: 9679167
references: Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5826-31
references: 15827116
references: J Neuropathol Exp Neurol. 2005 Jul;64(7):605-12
references: 16042312
references: Science. 2006 Jun 2;312(5778):1389-92
references: 16741123
references: Exp Neurol. 2006 Sep;201(1):120-30
references: 16753145
references: J Neurosci. 2006 Nov 8;26(45):11798-806
references: 17093100
references: Nat Neurosci. 2007 May;10(5):615-22
references: 17435755
references: Hum Mol Genet. 2003 Oct 1;12(19):2519-32
references: 12915461
references: J Neurosci. 2000 Jan 1;20(1):123-32
references: 10627588
references: J Neurosci. 2000 Jan 1;20(1):240-50
references: 10627601
references: J Neurosci. 2000 Jan 15;20(2):660-5
references: 10632595
references: J Neurochem. 2000 Apr;74(4):1666-73
references: 10737625
references: J Neurol Sci. 2000 Nov 1;180(1-2):29-34
references: 11090861
references: J Neurosci. 2001 May 15;21(10):3369-74
references: 11331366
references: Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1604-9
references: 11818550